CA Patent

CA2739436C — Use of rifaximin for treating hepatic encephalopathy

Assigned to Salix Pharmaceuticals Inc · Expires 2019-08-27 · 7y expired

What this patent protects

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

USPTO Abstract

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

Drugs covered by this patent

Patent Metadata

Patent number
CA2739436C
Jurisdiction
CA
Classification
—
Expires
2019-08-27
Drug substance claim
No
Drug product claim
No
Assignee
Salix Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.